Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Snap-on Inc Director's Dealing 2023

Mar 17, 2023

30335_dirs_2023-03-17_38ce8ac0-0f53-4876-bbad-95e9577a93c2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Snap-on Inc (SNA)
CIK: 0000091440
Period of Report: 2023-03-16

Reporting Person: PINCHUK NICHOLAS T (Director, Chairman, President and CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-03-16 Common Stock M 32500 $109.43 Acquired 699729.4282 Direct
2023-03-16 Common Stock S 5254 $234.1422 Disposed 694475.4282 Direct
2023-03-16 Common Stock S 2724 $235.1695 Disposed 691751.4282 Direct
2023-03-16 Common Stock S 8416 $236.5279 Disposed 683335.4282 Direct
2023-03-16 Common Stock S 5806 $237.2612 Disposed 677529.4282 Direct
2023-03-16 Common Stock S 600 $238.3792 Disposed 676929.4282 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-03-16 Stock Option (Right to Buy) $109.43 M 32500 Disposed 2024-02-13 Common Stock (32500) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 810.8716 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $144.69 2025-02-12 Common Stock (130000) 130000 Direct
Stock Option (Right to Buy) $138.03 2026-02-11 Common Stock (135000) 135000 Direct
Stock Option (Right to Buy) $168.70 2027-02-09 Common Stock (135000) 135000 Direct
Stock Option (Right to Buy) $161.18 2028-02-15 Common Stock (92288) 92288 Direct
Stock Option (Right to Buy) $155.92 2029-02-14 Common Stock (83059) 83059 Direct
Stock Option (Right to Buy) $155.34 2030-02-13 Common Stock (83059) 83059 Direct
Stock Option (Right to Buy) $189.89 2031-02-11 Common Stock (40687) 40687 Direct
Stock Option (Right to Buy) $211.67 2032-02-10 Common Stock (32286) 32286 Direct
Stock Option (Right to Buy) $249.26 2033-02-09 Common Stock (24295) 24295 Direct
Restricted Stock Units $ 2024-02-11 Common Stock (6344) 6344 Direct
Restricted Stock Units $ 2025-02-10 Common Stock (5519) 5519 Direct
Restricted Stock Units $ 2026-02-09 Common Stock (5549) 5549 Direct
Performance Units $ Common Stock (19033) 19033 Direct
Performance Units $ Common Stock (16558) 16558 Direct
Performance Units $ Common Stock (16645) 16645 Direct
Deferred Stock Units $ Common Stock (24273.4145) 24273.4145 Direct

Footnotes

F1: The option was exercised, and a portion of the underlying shares were sold to cover the exercise price and estimated tax liability, pursuant to a Rule 10b5-1 Plan.

F2: Includes 1.4317 shares acquired under a dividend reinvestment plan.

F3: This transaction was executed in multiple trades at prices ranging from $233.61 to $234.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effectuated.

F4: This transaction was executed in multiple trades at prices ranging from $234.73 to $235.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effectuated.

F5: This transaction was executed in multiple trades at prices ranging from $235.90 to $236.895. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effectuated.

F6: This transaction was executed in multiple trades at prices ranging from $236.95 to $237.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effectuated.

F7: This transaction was executed in multiple trades at prices ranging from $238.15 to $238.695. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effectuated.

F8: Option fully vested.

F9: Exercise of Rule 16b-3 stock option pursuant to a Rule 10b5-1 Plan.

F10: Original stock option grant vests in three annual installments beginning on the date listed in the "Date Exercisable" column.

F11: 1 for 1.

F12: The restricted stock units vest three years from the grant date on the date listed above, assuming continued employment.

F13: If the Company achieves certain goals over the 2021-2023 period, the performance units will vest and stock will be awarded. The target number of units that may be earned is reported above; the maximum amount is 200% of the number reported, subject to plan limits.

F14: If the Company achieves certain goals over the 2022-2024 period, the performance units will vest and stock will be awarded. The target number of units that may be earned is reported above; the maximum amount is 200% of the number reported, subject to plan limits.

F15: If the Company achieves certain goals over the 2023-2025 period, the performance units will vest and stock will be awarded. The target number of units that may be earned is reported above; the maximum amount is 200% of the number reported, subject to plan limits.

F16: Payment will be made in accordance with the reporting person's deferral election, death, disability or termination of employment.